Stereotactic radiotherapy is a new option in the treatment of prostate cancer.
However, only retrospective series and a few prospective phase II trials are available at this moment, including a few thousands of patients with a short follow-up. Most of the protocols delivered 33 to 38Gy in four or five fractions. Acute toxicity seems to be similar to the one observed after conventional radiotherapy. Late toxicity is less evaluable because of the short follow-up: the rate of radiation-induced proctitis seems low in the published series. Urinary toxicities are not properly evaluated: some series reported a high incidence of urinary complications grade or higher. Most of the patients belong to the D'Amico's favourable group: biochemical controls are equivalent to those observed after conventional irradiation, but the follow-up is often shorter than 5 years and no definitive conclusion could be made about the efficiency of the technique. Data for the intermediate and high risk groups are not mature. In conclusion, stereotactic radiotherapy could strongly modified the management of prostate cancer: some phase III trials have started to confirm the good results reported in preliminary series.
Written by:
Quero L, Hennequin C. Are you the author?
Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefeaux, 75475 Paris, France; Université Paris-Diderot Paris VII, 1, avenue Claude-Vellefeaux, 75475 Paris, France. ;
Reference: Cancer Radiother. 2014 Jun 20. pii: S1278-3218(14)00099-7.
doi: 10.1016/j.canrad.2014.05.008
Mixed element/text selectionPubMed Abstract
PMID: 24958683
Article in French.
UroToday.com Prostate Cancer Section
